Welcome to the Hope Bio Blog

By Jan Shultis During the last few weeks of 2025, Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) received Food and Drug Administration (FDA) authorization to administer Hope Biosciences’ allogeneic (donor) adipose-derived mesenchymal (adult) stem cells (HB-adMSCs) to seven men and women living with Multiple System Atrophy (MSA). As HBRF shared in their announcement, the occasion is noteworthy both for authorization of research in a rar

FOR IMMEDIATE RELEASE By Jan Shultis Sugar Land, Texas, 3 February 2026 - A multicenter trial stretching across the southwestern United States is now recruiting patients to investigate whether allogeneic (donor-derived) Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) can prevent progression of trauma-induced Acute Kidney Injury (AKI), an abrupt decline in renal function that occurs over hours to days in up to 50% of trauma and burn patients and has few eff

Happy, happy 2026, Hope community! One of our favorite parts of welcoming a new year is to reflect on the period concluding. There are many ways to present annual reviews, and in the near-decade since our founding we have tried many, from formal materials and presentations to stakeholder reports. This year, however, we’re trying something new – we want to celebrate the year with those who made it possible, in plain language. We want to celebrate with you. If you prefer to